Logo wahanariau.com
  2. Zenas biopharma

Zenas biopharma

Index
Globenewswire

Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences

Kamis, 07 November 2024 - 19:30:00 Wib
Globenewswire

Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

Jumat, 20 September 2024 - 07:31:20 Wib
Globenewswire

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Jumat, 13 September 2024 - 12:00:00 Wib
Globenewswire

Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer

Senin, 01 Juli 2024 - 22:17:46 Wib
Globenewswire

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Rabu, 08 Mei 2024 - 10:51:58 Wib
Globenewswire

Zenas BioPharma Mengangkat Patricia Allen sebagai Anggota Direksinya

Kamis, 07 Maret 2024 - 14:18:03 Wib
Globenewswire

Zenas BioPharma Appoints Patricia Allen to its Board of Directors

Kamis, 07 Maret 2024 - 04:57:04 Wib
Globenewswire

Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer

Senin, 04 Desember 2023 - 22:00:00 Wib
Globenewswire

Zenas BioPharma Memperkuat Jajaran Pemimpin dengan Mengangkat Jennifer Fox sebagai Chief Business Officer dan Chief Financial Officer serta Tanya Fischer, M.D., PhD. sebagai Head of R&D dan Chief Medical Officer

Senin, 04 Desember 2023 - 22:00:00 Wib
Globenewswire

Zenas BioPharma Umumkan Lisensi Strategis dan Perjanjian Kolaborasi dengan Bristol Myers Squibb untuk Mengembangkan dan Mengomersialkan Antibodi Dwifungsi Baru Obexelimab di Jepang, Korea Selatan, Taiwan, Singapura, Hong Kong, dan Australia

Selasa, 05 September 2023 - 22:07:00 Wib
Globenewswire

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia

Selasa, 05 September 2023 - 22:04:00 Wib
Globenewswire

Zenas BioPharma Umumkan Publikasi Studi Fase 2 Obexelimab, Pengobatan Investigatif untuk Penyakit Terkait IgG4, di Jurnal The Lancet Rheumatology

Kamis, 03 Agustus 2023 - 23:01:00 Wib
Globenewswire

Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease, in The Lancet Rheumatology

Selasa, 01 Agustus 2023 - 22:06:00 Wib